Latest Articles

Publication Date
Case Report: Long-term maintenance of GnRH-a combined with dienogest for thoracic endometriosis syndrome.

Thoracic endometriosis syndrome is a rare form of endometriosis in which endometrial tissue is thought to migrate to the lungs and, with the onset of menstruation, the ectopic foci bleed, …

Published: Oct. 27, 2025, midnight
The effects of endocrine disruptors on the female reproductive system.

Endocrine-disrupting chemicals (EDCs) are a diverse, comprehensive group of mostly synthetic chemicals that disrupt many physiological functions in humans and animals. EDCs are particularly disruptive to the female reproductive system. …

Published: Oct. 9, 2025, midnight
Kuntai Capsule for the Treatment of Menopausal Symptoms Induced by GnRH-a Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Gonadotropin-releasing hormone agonists (GnRH-a) often induce menopausal symptoms, negatively affecting women's psychological, emotional, and physical health. Kuntai capsule is widely used in clinical practice to alleviate various menopausal symptoms. Exploring …

Published: Oct. 3, 2025, midnight
GnRH agonist pretreatment in hormonal endometrial preparation: a comparison of two protocols for frozen embryo transfer outcomes.

The aim of this study was to compare the effects of different endometrial treatment regimens on the outcome of frozen embryo transfer (FET).

Published: Oct. 1, 2025, midnight
Deep pelvic endometriosis: clinical features, diagnosis, and treatment - a comprehensive review.

Deep infiltrative endometriosis (DIE) is characterized by the infiltration of endometrial tissue into the pelvic organs, such as the rectovaginal septum, utero-ovarian, and uterosacral ligaments. Bowel involvement occurs in approximately …

Published: Sept. 30, 2025, midnight
Cost-effectiveness of dienogest compared to gonadotropin releasing hormone agonists for the management of endometriosis in Vietnam.

Endometriosis-related dysmenorrhea and pelvic pain impose significant economic and quality-of-life burdens. This study evaluated the cost-effectiveness of dienogest compared to gonadotropin-releasing hormone agonists (GnRH-a) for managing dysmenorrhea and pelvic pain …

Published: Sept. 29, 2025, midnight
Pharmacogenomic analysis of alarelin acetate-induced hepatotoxicity: a case report and literature review.

Alarelin acetate, a synthetic gonadotropin-releasing hormone (GnRH) analogue, is widely used to manage endometriosis and hormone-sensitive malignancies. Although its safety profile is generally favorable, we report the first documented case …

Published: Sept. 29, 2025, midnight
The role of pre-operative gonadotrophin-releasing hormone agonists (GnRHa) on pain, bowel and bladder symptoms in rectovaginal/colorectal endometriosis surgery: a multicenter cohort study.

The efficacy of medical and surgical treatment of endometriosis-associated pain is a source of ongoing controversy. There is a lack of evidence about gonadotropin-releasing hormone agonists (GnRHa) use on long-term …

Published: Sept. 23, 2025, midnight
Tolerability and Shared Decision-Making in the Hormonal Management of Endometriosis-Associated Pain.

Background: The management of endometriosis-associated pain has traditionally focused on analgesic efficacy. However, with high-level evidence demonstrating therapeutic equivalence among principal hormonal classes, the paradigm has shifted towards a patient-centred …

Published: Sept. 18, 2025, midnight
Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States.

Endometriosis symptoms have multifaceted manifestations, and there are few approved nonsurgical treatment options. Gonadotropin-releasing hormone (GnRH) agonists/antagonists for endometriosis vary on efficacy, safety profile, and out-of-pocket (OOP) cost, among other …

Published: Sept. 7, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!